JASPER THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
JASPER THERAPEUTICS, INC. (JSPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $900.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-05-14
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $900.00K, a 66.67% decline year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $2.50M, a 66.67% increase year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $2.70M, a 58.82% increase year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-12-31 was $1.00M, a 42.86% increase year-over-year.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $7.50M, a 36.36% increase from fiscal 2024.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $5.50M, a 61.76% increase from fiscal 2023.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $3.40M, a 88.89% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $1.80M, a 28.57% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-03-31 | $900.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $7.50M 10-K · filed 2026-03-30 | |||
| 2025-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $5.20M 10-Q · filed 2025-08-13 | $6.20M derived: sum of 3 quarters · filed 2026-05-14 | $7.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-03-31 | $2.70M 10-Q · filed 2026-05-14 | $3.70M derived: sum of 2 quarters · filed 2026-05-14 | $5.00M derived: sum of 3 quarters · filed 2026-05-14 | $6.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.30M derived: sum of 2 quarters · filed 2026-03-30 | $3.80M derived: sum of 3 quarters · filed 2026-03-30 | $5.50M 10-K · filed 2026-03-30 |
| 2024-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.80M derived: sum of 2 quarters · filed 2025-08-13 | $4.50M 10-Q · filed 2024-11-07 | $5.20M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.20M 10-Q · filed 2025-08-13 | $3.90M derived: sum of 3 quarters · filed 2025-08-13 | $4.50M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.70M 10-Q · filed 2025-05-12 | $2.40M derived: sum of 2 quarters · filed 2025-05-12 | $3.00M derived: sum of 3 quarters · filed 2025-05-12 | $3.60M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.30M derived: sum of 2 quarters · filed 2025-02-28 | $1.90M derived: sum of 3 quarters · filed 2025-02-28 | $3.40M 10-K · filed 2025-02-28 |
| 2023-09-30 | $600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.20M derived: sum of 2 quarters · filed 2024-11-07 | $2.70M 10-Q · filed 2024-11-07 | $3.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.10M 10-Q · filed 2024-08-13 | $2.90M derived: sum of 3 quarters · filed 2024-08-13 | $3.10M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-14 | $2.30M derived: sum of 2 quarters · filed 2024-05-14 | $2.50M derived: sum of 3 quarters · filed 2024-05-14 | $2.90M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.00M derived: sum of 2 quarters · filed 2024-03-05 | $1.40M derived: sum of 3 quarters · filed 2024-03-05 | $1.80M 10-K · filed 2024-03-05 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $600.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.00M 10-Q · filed 2023-11-09 | $1.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $800.00K 10-Q · filed 2023-08-11 | $1.00M derived: sum of 3 quarters · filed 2023-08-11 | |
| 2022-03-31 | $400.00K 10-Q · filed 2022-05-12 | $600.00K derived: sum of 2 quarters · filed 2023-03-08 | ||
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.40M 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | $800.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |